前列腺癌患者血清miR—146a與miR—152的表達(dá)水平及臨床意義

戴金華 廖于峰 冷江涌 馬建波 李克強(qiáng)

【摘要】目的：分析前列腺癌患者血清miR-146a與miR-152的表達(dá)水平及臨床意義。 方法：以2009年1月至2013年4月在我院泌尿外科診治的前列腺癌、良性前列腺增生患者及健康體檢志愿者各46例為研究對(duì)象，分析各組患者血清miR-146a與miR-152的表達(dá)水平及與臨床病理參數(shù)之間的關(guān)系。結(jié)果：miR-146a在前列腺癌患者血清中的表達(dá)水平顯著高于良性前列腺增生及正常組血清，且前列腺良性增生組血清中miR-146a的表達(dá)量亦較正常組高，差異均具有統(tǒng)計(jì)學(xué)意義（P<0.05）；miR-152在前列腺癌患者較良性前列腺增生及正常組血清顯著偏低（P<0.05），但在良性前列腺增生和正常組之間無統(tǒng)計(jì)學(xué)差異（P>0.05）；血清miR-146a在不同病理分期、臨床分期、有無骨轉(zhuǎn)移及血清tPSA有關(guān)（P<0.05），與年齡無關(guān)（P>0.05）；而miR-152與不同病理分期、臨床分期、有無骨轉(zhuǎn)移有關(guān)（P<0.05），與血清tPSA水平無相關(guān)性（P>0.05），與年齡無顯著相關(guān)性（P>0.05）。 結(jié)論：miR-146a與miR-152在前列腺癌患者血清中的表達(dá)水平發(fā)生了顯著改變，為用于前列腺癌的早期診斷及病程的判斷提供了相關(guān)實(shí)驗(yàn)依據(jù)。

【關(guān)鍵詞】前列腺癌；血清；miR-146a；miR-152

Serum miR-146a and miR-152 expression levels of prostate cancer patients and their clinical significanceDAI Jinhua1， LIAO Yufeng1△， LENG Jiangyong2， MA Jianbo1， LI Keqiang2. 1.Department of Clinical Laboratory， Ningbo Second Hospital， Ningbo 315010， Zhejiang， China； 2.Urology Department，Ningbo Second Hospital， Ningbo 315010， Zhejiang， China

【Abstract】Objectives： To analyze serum circulating miR-146a and miR-152 expression levels of prostate cancer patients and their clinical significance. Methods： Prostate cancer， benign prostatic hyperplasia patients and healthy volunteers from July 2012 to April 2013 in our hospital were recruited for the study， 46 cases in each group. The serum miR-146a， miR-152 expression levels and correlativity with clinic pathological parameters were analyzed. Results： The miR-146a expression levels in the serum of prostate cancer group was significantly higher than these in benign prostatic hyperplasia group and normal group， and miR-146a expression levels in the serum of benign prostatic hyperplasia group was higher than normal group， with statistically significant difference （P< 0.05）； miR-152 in prostate cancer group was decreased significantly compared with benign prostatic hyperplasia group and normal group （P<0.05）， but no significant difference was found between benign prostatic hyperplasia and normal group （P> 0.05 ） ； serum miR-146a was related with different pathological stage， clinical stage， with or without bone metastases （P<0.05）. Serum miR-146a had no relationship with serum tPSA （p>0.05）； whereas miR-152 was related with various pathologic stage， clinical stage， with or without bone metastasis （P<0.05）， but serum tPSA levels had no correlation with miR-152 （P> 0.05）. Conclusion： Serum miR-146a and miR-152 expression levels of prostate cancer patients have significant changes， which provides relevant experimental basis for the early diagnosis of prostate cancer and determine the course.

【Key words】Prostate cancer； Serum； MiR-146a； MiR-152

【中圖分類號(hào)】R697+.3【文獻(xiàn)標(biāo)志碼】A

前列腺癌（prostate cancer，PCa）是常見的男性生殖系統(tǒng)惡性腫瘤之一，發(fā)病率隨著年齡的增長(zhǎng)而升高，且呈現(xiàn)出地區(qū)差異性。我國(guó)前列腺癌的發(fā)病率雖較歐美地區(qū)低，但隨著人口老齡化進(jìn)程的加快和飲食結(jié)構(gòu)的改變，其發(fā)病率逐年上升，呈現(xiàn)出惡性程度高、預(yù)后差等特點(diǎn)[1]。微小RNA（MicroRNA）是一類高度保守內(nèi)源性非編碼的小核苷酸序列，近年MicroRNA所介導(dǎo)的基因轉(zhuǎn)錄后調(diào)控的研究成果為前列腺癌發(fā)病機(jī)制及早期診斷的研究開辟了新的思路[2]。研究顯示miR-146a在早期前列腺癌中表達(dá)有所升高，可能參與前列腺癌的發(fā)生發(fā)展過程[3]。針……